ProCE Banner Activity

ExpressPoints:
Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches

Slideset

Download this expert-selected summary slideset on treating patients with AML.

Released: December 22, 2021

Expiration: December 21, 2022

Share

Faculty

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Daniel A. Pollyea

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Bristol Myers Squibb

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Daniel A. Pollyea, MD, MS: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Kura, Link, Magenta, Novartis, OncoVerity, Qihan, Rigel, Ryvu, Syros, Sumitomo, Zentalis.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, CTI Biopharma, Daiichi Sankyo, Gilead, GlaxoSmithKline, Immunogen, Johnson & Johnson, Kite, Kura, Novartis, Qiagen, Rigel, Schrodinger, Sellas, Stemline, Sumitomo, Syndax.